Treatment of chronic Chagas' disease with itraconazole and allopurinol

American Journal of Tropical Medicine and Hygiene

Volumn 59, Issue 1, 1998, Pages 133-138

  Apt, Werner ^a,e   Aguilera, Ximena ^a   Arribada, Arturo ^b   Pérez, Carlos ^a   Miranda, Claudio ^a   Sánchez, Gittith ^a   Zulantay, Inés ^a   Cortés, Pedro ^a   Rodriguez, Jorge ^c   Juri, Daniel ^d  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL SAN BORJA ARRIARÁN   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

^d Ophthalmology Service   (Argentina)

^e NONE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZNIDAZOLE; ITRACONAZOLE; NEOQUIPENIL; NIFURTIMOX; PRIMAQUINE; RAGONIL; UNCLASSIFIED DRUG; UROGOTAN; ZILORIC;

ARTICLE; CHAGAS DISEASE; CHRONIC DISEASE; CONTROLLED STUDY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; RASH; SEROLOGY; STEVENS JOHNSON SYNDROME; TREATMENT INDICATION; TREATMENT OUTCOME; TRYPANOSOMA CRUZI;

EID: 17944384088     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1998.59.133     Document Type: Article

References (35)

1. WHO, 1991. Control of Chagas' disease. World Health Organ Tech Rep Ser 811.
2. Schofield CJ, 1992. Eradication of Triatoma infestons: a new regional programme for southern Latin America. Ann Soc Belg Med Trop 72 (suppl 1): 69-70.
3. Arribada A, Apt W, Aguilera X, Solari A, Ugarte JM, Sandoval J, Arribada M, 1993. Cardiopatia chagásica en Chile. Cardiol Int 2: 94-99.
4. Apt W, Reyes H, 1990, Enfermedad de Chagas' en Latinoamérica. Parasitol Dia 14: 23-40.
5. Urbina JA, Payares G, Molina J, Sanoia C, Liendo A, Lazardi K, Piras M, Piras R, Perez N, Wincker P, Ryley J, 1996. Cure of short- and long-term experimental Chagas' disease using DO870. Science 273: 969-911.
6. Apt W, Aguilera X, Pérez C, Miranda C, Zulantay I, Apt P, Cortes P, Rodriguez J, 1994. Tratamiento de la enfermedad de Chagas' humana crónica con itraconazol y alopurinol. Informe preliminar. Rev Med Chil 122: 420-427.
7. Aguilera X, Apt W, Arribada A, 1987. Evaluación del alopurinol en la enfermedad de Chagas crónica humana en Chile. Parasitol Dia 11: 132-134.
8. Andrade SG, Magalhaes JB, Pontes AL, 1989. Terapeutica da fase cronica da infeccao experimental pelo Trypanosoma cruzi com o benznidazol e/o nifurtimox. Rev Soc Bras Med Trop 22: 113-118.
9. Gallerano R, Marr J, Soza R, 1990. Therapeutic efficacy of allopurinol in patients with chronic Chagas' disease. Am J Trop Med Hyg 43: 159-166.
10. Brener Z, Cancado JR, Da Cunha LM, Da Luz MP, De Soule L, Scares ME, Santos L, Cancado CB, 1993. An experimental and clinical assay with ketoconazole in the treatment of Chagas' disease. Mem Inst Oswaldo Cruz 88: 149-153.
11. De Castro SL, 1993. The challenge of Chagas' disease chemotherapy: an update of drugs assayed against Trypanosoma cruzi. Acta Trop 53: 83-98.
12. Viotti R, Vigleain C, Aumento H, Segura E, 1994. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long term follow up. Am Heart J 127: 151-162.
13. Levi GC, Lobo MF, Kallas EG, Amato Neto V, 1996. Etioiogical drug treatment of human infection by Trypanosoma cruzi. Rev Inst Med Trop Sao Paulo 38: 35-38.
14. MacCabe R, Remington J, Araujo F, 1986. In vitro and in vivo effects of itraconazole against Trypanosoma cruzi. Am J Trop Med Hyg 35: 280-284.
15. Cutsem VJ, Van Gerven F, Janssen P, 1987. The in vitro and in vivo antifungal activity of itraconazole. Fromtling RA, ed. Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Beerse, Belgium: Prous Science Publishing Co., 5-20.
16. Bossdie H, 1987. Itraconazole: a selective inhibitor of the cytochromic R 450 dependent ergosterol biosynthesis. Fromtling RA, ed. Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Beerse, Belgium: Prous Science Publishing Co., 39-53.
17. Heykants J, Michieless M, Meuidermans J, Monbaliu J, Lawnpen K, Van Peer A, Levron J, Woestenborglas R, Couwenbergh G, 1987. The pharmacokinetics of itraconazole in animals and man: an overview. Fromtling RA, ed. Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Beerse, Belgium: Prous Science Publishing Co., 57-82.
18. Van Cauteren H, Coussement W, Vandenbughe J, Klerin V, Vamparys PH, Marsboom R, 1987. The toxicological properties of itraconazole. Fromtling RA, ed. Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Beerse, Belgium: Prous Science Publishing Co., 101-108.
19. Knierim F, Sandoval J, Munoz E, 1973. Reacción de hemaglutinación indirecta en la enfermedad de Chagas crónica. Bol Chil Parasitol 28: 54-57.
20. Camargo M, 1966. Fluorescent antibody rest for the serodiagnosis of American trypanosomiasis. Technical modification employing preserved culture forms of Trypanosoma cruzi in a slide test. Rev Inst Med Trop Sao Paulo 8: 227-234.
21. Voller A, 1975. Microplate enzyme-linked immunoabsorbent assay for Chagas' disease. Lancet 1: 426-428.
22. Jazin EE, Luquetti AO, Rassi A, Frash AC, 1991. Shift of excretory-secretory immunogens of Trypanosoma cruzi during human Chagas' disease. Infect Immun 59: 2189-2191.
23. Coding J, Handman E, 1984. Electrophoretic analysis of protein antigens. Morel C, ed. Genes and Antigens of Parasites. Rio de Janeiro: UNDP-World Bank. WHO Special Program of Research and Training in Tropical Diseases, 385-415.
24. Krettli AU, Cancado JR, Brener Z, 1982. Effect of specific chemotherapy on the levels of lytic antibodies in Chagas' disease. Trans R Soc Trop Hyg 76: 334-340.
25. Krettli A, Cancado R, Brener Z, 1984. Criterion of cure of human Chagas' disease after specific chemotherapy: recent advances. Mem Inst Oswaldo Cruz 79: 157-164.
26. Galvao LM, Nunes RM, Cancado JR, Brener Z, Krettli AU, 1993. Lytic antibody titres as a means of assessing cure after treatment of Chagas' disease: a 10 years follow up study. Trans R Soc Trop Med Hyg 87: 220-223.
27. Gazzinelli RT, Galvao LM, Krautz G, Lima PC, Cancado JR, Sharfstein J, Krettli AU, 1993. Use of Trypanosoma cruzi purified glycoprotein (Gp57/51) or trypomastigote shed antigens to assess cure of human Chagas' disease. Am J Trop Med Hyg 49: 625-635.
28. Nomenclatura, 1985. Criticos Diagnósticos Electrocardiográficos en la Cardiopatia Chagásica Crónica. Programa de Salud Humano. B.I.D. Ministerio de Salud. Universidad del Salvador, 5-28.
29. Chiari E, Dias JC, Lana M, Chiari C, 1989. Hemocultures for the parasitological diagnosis of human chronic Chagas' disease. Rev Soc Bras Med Trop 22: 19-23.
30. Apt W, Arribada A, Arab F, Ugarte JM, Luksic J, Sole C, 1986. Clinical trial of benznidazole and an immunopotentiator against Chagas' disease in Chile. Trans R Soc Trop Med Hyg 80: 1010.
31. Sanchez G, Zulantay I, Venegas J, Solari A, Galvez R, Peña P, Rodriguez J, Apt W, 1995. Treatment with allopurinol and itraconazole changes lytic activity in patients with chronic low grade Trypanosoma cruzi infection. Trans R Soc Trop Med Hyg 89: 438-439.
32. Schenone H, Alfaro E, Rojas A, 1974. Bases y rendimiento del xenodiagnóstico en la infección Chagásica humana. Bol Chile Parasitol 29: 24-27.
33. Wendel S, Brener Z, Camargo M, Rassi A, eds., 1992. Chagas' Disease (American Trypanosomiasis) Its impact on Transfusion and Clinical Medicine. Brazil: Sao Paulo: International Society of Blood Transfusion, 89-99.
34. Arribada A, Apt W, Ugarte J, 1986. A four year follow up survey of chagasic cardiopathy in Chile. Bull Pan Am Health Organ 20: 254-266.
35. Andrade Z, 1994. Extracellular matrix degradation in parasitic disease. Braz J Med Biol Res 27: 2273-2281.